BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 32045054)

  • 21. Design, synthesis and biological evaluation of novel 1
    Liu J; Wen Y; Gao L; Gao L; He F; Zhou J; Wang J; Dai R; Chen X; Kang D; Hu L
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):72-84. PubMed ID: 31682465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation.
    Marzouk AA; Abdel-Aziz SA; Abdelrahman KS; Wanas AS; Gouda AM; Youssif BGM; Abdel-Aziz M
    Bioorg Chem; 2020 Sep; 102():104090. PubMed ID: 32683176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, Synthesis, and Cytotoxic Evaluation of Certain 7-Chloro-4-(piperazin-1-yl)quinoline Derivatives as VEGFR-II Inhibitors.
    Aboul-Enein MN; El-Azzouny AM; Ragab FA; Hamissa MF
    Arch Pharm (Weinheim); 2017 Apr; 350(3-4):. PubMed ID: 28304102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors.
    Shi L; Wu TT; Wang Z; Xue JY; Xu YG
    Eur J Med Chem; 2014 Sep; 84():698-707. PubMed ID: 25064347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation.
    Abdel-Mohsen HT; Girgis AS; Mahmoud AEE; Ali MM; El Diwani HI
    Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900089. PubMed ID: 31463965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking.
    Eldehna WM; Fares M; Ibrahim HS; Aly MH; Zada S; Ali MM; Abou-Seri SM; Abdel-Aziz HA; Abou El Ella DA
    Eur J Med Chem; 2015 Jul; 100():89-97. PubMed ID: 26071861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New thiazolidine-2,4-diones as potential anticancer agents and apoptotic inducers targeting VEGFR-2 kinase: Design, synthesis, in silico and in vitro studies.
    Elkady H; Mahdy HA; Taghour MS; Dahab MA; Elwan A; Hagras M; Hussein MH; Ibrahim IM; Husein DZ; Elkaeed EB; Alsfouk AA; Metwaly AM; Eissa IH
    Biochim Biophys Acta Gen Subj; 2024 Jun; 1868(6):130599. PubMed ID: 38521471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N-Substituted-4-phenylphthalazin-1-amine-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluation studies.
    El-Adl K; Ibrahim MK; Khedr F; Abulkhair HS; Eissa IH
    Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000219. PubMed ID: 33197080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of thieno[2,3-d]pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents.
    El-Metwally SA; Abou-El-Regal MM; Eissa IH; Mehany ABM; Mahdy HA; Elkady H; Elwan A; Elkaeed EB
    Bioorg Chem; 2021 Jul; 112():104947. PubMed ID: 33964580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis.
    Alsaif NA; Dahab MA; Alanazi MM; Obaidullah AJ; Al-Mehizia AA; Alanazi MM; Aldawas S; Mahdy HA; Elkady H
    Bioorg Chem; 2021 May; 110():104807. PubMed ID: 33721808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increasing the binding affinity of VEGFR-2 inhibitors by extending their hydrophobic interaction with the active site: Design, synthesis and biological evaluation of 1-substituted-4-(4-methoxybenzyl)phthalazine derivatives.
    Eldehna WM; Abou-Seri SM; El Kerdawy AM; Ayyad RR; Hamdy AM; Ghabbour HA; Ali MM; Abou El Ella DA
    Eur J Med Chem; 2016 May; 113():50-62. PubMed ID: 26922228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazoline and diarylamide fragments.
    Wang R; Liu H; You YY; Wang XY; Lv BB; Cao LQ; Xue JY; Xu YG; Shi L
    Bioorg Med Chem Lett; 2021 Mar; 36():127788. PubMed ID: 33460739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel quinazolin-2-yl 1,2,3-triazole hybrids as promising multi-target anticancer agents: Design, synthesis, and molecular docking study.
    El Hamaky NFM; Hamdi A; Bayoumi WA; Elgazar AA; Nasr MNA
    Bioorg Chem; 2024 Jul; 148():107437. PubMed ID: 38749114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors.
    Zeidan MA; Mostafa AS; Gomaa RM; Abou-Zeid LA; El-Mesery M; El-Sayed MA; Selim KB
    Eur J Med Chem; 2019 Apr; 168():315-329. PubMed ID: 30826508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors.
    El-Helby AA; Sakr H; Eissa IH; Abulkhair H; Al-Karmalawy AA; El-Adl K
    Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900113. PubMed ID: 31448458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of novel indolyl-1,2,4-triazole hybrids as potent vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors with potential anti-renal cancer activity.
    Al-Hussain SA; Farghaly TA; Zaki MEA; Abdulwahab HG; Al-Qurashi NT; Muhammad ZA
    Bioorg Chem; 2020 Dec; 105():104330. PubMed ID: 33038552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis, molecular docking, in silico ADMET profile and anticancer evaluations of sulfonamide endowed with hydrazone-coupled derivatives as VEGFR-2 inhibitors.
    Sayed AM; Taher FA; Abdel-Samad MRK; El-Gaby MSA; El-Adl K; Saleh NM
    Bioorg Chem; 2021 Mar; 108():104669. PubMed ID: 33515863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation.
    Alanazi MM; Mahdy HA; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Dahab MA; Eissa IH
    Bioorg Chem; 2021 Jul; 112():104949. PubMed ID: 34023640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase.
    Alsaif NA; Elwan A; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Mahdy HA; Taghour MS
    Mol Divers; 2022 Aug; 26(4):1915-1932. PubMed ID: 34460053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors.
    Sun W; Hu S; Fang S; Yan H
    Bioorg Chem; 2018 Aug; 78():393-405. PubMed ID: 29677483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.